Amoxicillin Clavulanate Suspension 200/28.5mg/5mL

Amoxicillin and Clavulanate Potassium Oral Suspension for Children 200 mg/28.5 mg per 5 mL
Item
Detail
Primary Container
Amber type III glass bottle (available in 35mL, 50mL, 75mL, or 100mL nominal capacity)
Closure
Child-resistant polypropylene screw cap with induction seal liner
Secondary Packaging
Printed cardboard carton with patient information leaflet (pediatric dosing guidance included)
Accessories
Calibrated oral dosing syringe (1mL / 5mL graduations) for accurate pediatric dosing
Carton Configuration
1 bottle per carton

Click to add this item to cart.

Product Description

Product NameAmoxicillin and Clavulanate Potassium Oral Suspension for Children
SpecificationAmoxicillin 200mg / Clavulanate Potassium 28.5mg per 5mL
Dosage FormOral Suspension (dry powder for reconstitution)
Active IngredientsAmoxicillin (as Amoxicillin Trihydrate); Clavulanate Potassium (equivalent to Clavulanic Acid)
Target PopulationPediatric patients (children)
Route of AdministrationOral
PackagingAmber glass bottle with child-resistant cap, supplied with calibrated oral dosing syringe
StorageStore dry powder below 25°C. After reconstitution, refrigerate between 2°C and 8°C and use within 7 days.
Shelf Life24 months (unopened, dry powder)

Product Overview

Amoxicillin and Clavulanate Potassium Oral Suspension for Children is a combination formulation specifically designed for pediatric use. Each 5mL of reconstituted suspension contains 200mg of amoxicillin and 28.5mg of clavulanate potassium (equivalent to 25mg of clavulanic acid), providing a carefully balanced ratio of active ingredients in a child-friendly liquid form.

Amoxicillin Clavulanate Suspension 200/28.5mg/5mL: What the Published Guidance Says

A broad portfolio spanning the WHO Access and Watch groups, supplied with the documentation that stewardship programmes and national tenders require.

This page collects the supply-relevant facts for Amoxicillin Clavulanate Suspension 200/28.5mg/5mL — specification, testing, packaging and the registration paperwork that travels with the batch.

  • WHO's own indication mapping is public — we align to it The WHO Antibiotics Portal lists amoxicillin as first choice for community-acquired pneumonia (mild to moderate), acute otitis media, acute sinusitis, acute pharyngitis and uncomplicated acute malnutrition in children; amoxicillin + clavulanic acid as first choice for severe community-acquired pneumonia in children, hospital-acquired pneumonia, cystitis and cellulitis; and ceftriaxone as first choice for severe acute pyelonephritis. WHO Antibiotics Portal — AWaRe
  • Access group — the empirical workhorses The WHO AWaRe classification places amoxicillin, amoxicillin + clavulanic acid, ampicillin, clindamycin, gentamicin, metronidazole, chloramphenicol and doxycycline in the Access group. These are the medicines expected to be available in every functioning health system. WHO AWaRe (Access, Watch, Reserve) classification of antibiotics
  • AWaRe is the framework buyers and stewards now work to WHO's AWaRe classification divides antibiotics into Access, Watch and Reserve. Access agents are described as those that should be widely available, affordable and quality-assured to improve access and promote appropriate use. Watch agents carry higher resistance potential and should be prioritised as targets of stewardship programmes and monitoring. WHO Antibiotics Portal — AWaRe

Each point above is reproduced because it has a practical consequence for Amoxicillin Clavulanate Suspension 200/28.5mg/5mL: the strength you can register, the pack you can release, or the wording permitted on the label. Your national prescribing information always takes precedence.

Amoxicillin Clavulanate Suspension 200/28.5mg/5mL: Specification, Pack & Documentation Summary

Product NameAmoxicillin and Clavulanate Potassium Oral Suspension for Children
SpecificationAmoxicillin 200mg / Clavulanate Potassium 28.5mg per 5mL
Dosage FormOral Suspension (dry powder for reconstitution)
Active IngredientsAmoxicillin (as Amoxicillin Trihydrate); Clavulanate Potassium (equivalent to Clavulanic Acid)
Route of AdministrationOral
StorageStore dry powder below 25°C. After reconstitution, refrigerate between 2°C and 8°C and use within 7 days.
Therapeutic groupAntibacterials — Antibacterials
ManufacturerSinophare Bio-technology Co., Ltd. (GMP, China)
Documentation suppliedCOA, HPLC/GC data, stability data, dossier package

The same therapeutic range is supplied in several presentations, so one purchase order can cover a mixed requirement: Amoxicillin Oral Suspension 400mg/5mL, Ampicillin 500mg Capsules, Azithromycin 400mg Capsules, Clarithromycin 250mg Capsules, Amoxicillin 500mg Capsules, Lincomycin 250mg Capsules, Norfloxacin 100mg Capsules, Oxytetracycline 250mg Capsules.

How Amoxicillin Clavulanate Suspension 200/28.5mg/5mL Is Tested and Released

Products are manufactured and tested against USP, EP, BP and CP monographs, with incoming raw-material inspection, in-process monitoring and full finished-product testing.

Release testing for Amoxicillin Clavulanate Suspension 200/28.5mg/5mL follows the monograph you nominate — USP, EP, BP or CP. If the presentation is not covered by a monograph, the specification is frozen in writing with your quality team before the batch is manufactured.

Standardised GMP production workshops with an independent R&D laboratory and a complete quality-inspection centre.

Release testing on this presentation is built around:

  • Testing for related substances and impurities
  • Testing for dissolution or release profile (solid oral forms)
  • Testing for uniformity of dosage units
  • Testing for water content and pH where applicable
  • Testing for sterility and bacterial endotoxins (parenterals and ophthalmics)
  • Testing for microbial limits and preservative efficacy (multi-dose presentations)

COA, HPLC and GC data, DMF and dossier packages, plus registration support documents for national marketing-authorisation filings.

How Amoxicillin Clavulanate Suspension 200/28.5mg/5mL Is Packed, Labelled and Shipped

  • Pack size: Amber glass bottle with child-resistant cap, supplied with calibrated oral dosing syringe. Non-standard pack sizes can be quoted against your artwork.
  • Storage: Store dry powder below 25°C. After reconstitution, refrigerate between 2°C and 8°C and use within 7 days..
  • Shelf life: 24 months (unopened, dry powder). Stability data for the marketed pack is included in the dossier.
  • Labelling: artwork can be produced in English, Arabic, French, Russian and Spanish, with your own brand and language mix, subject to the labelling rules of the destination market.
  • Export: GMP certificate, COA, certificate of origin, packing list and, where required, the free-sale or marketing authorisation certificate from the country of manufacture.

Regulatory Support for Amoxicillin Clavulanate Suspension 200/28.5mg/5mL

The legal manufacturer named on every document for Amoxicillin Clavulanate Suspension 200/28.5mg/5mL is Sinophare Bio-technology Co., Ltd., DML Number Jin20160068 (medicines) and Jin20160069 (paracetamol API).. The same entity appears on the GMP certificate and on the dossier submitted to your regulator.

  • Batch manufacturing and packaging records released for inspection on request during supplier audits.
  • Re-test or renewal support when the marketing authorisation comes up for variation or renewal.
  • CTD dossier modules 1–5 in editable and PDF form, with the finished-product and API sections cross-referenced.
  • Site Master File and GMP certificate for the manufacturing workshops.
  • Method validation, stability protocol and the shelf-life justification for the marketed pack.

Amoxicillin Clavulanate Suspension 200/28.5mg/5mL is presented here against antibacterials classified in the WHO AWaRe framework. Inclusion in an essential-medicines list does not authorise sale in any particular country — the marketing authorisation for that market is a separate step.

Questions We Are Asked About Amoxicillin Clavulanate Suspension 200/28.5mg/5mL

What pack size is available for Amoxicillin Clavulanate Suspension 200/28.5mg/5mL?

Standard commercial packaging for this line is Amber glass bottle with child-resistant cap, supplied with calibrated oral dosing syringe. Alternative pack sizes are produced to your specification and are supported by the corresponding stability data.

What documentation comes with a shipment of Amoxicillin Clavulanate Suspension 200/28.5mg/5mL?

The documentation set for every shipment includes the certificate of analysis (description, identification, assay, related substances), stability data for the marketed pack, and the site GMP certificate. Shelf life: 24 months.

Does the batch documentation for Amoxicillin Clavulanate Suspension 200/28.5mg/5mL support a registration filing?

The documentation set for every shipment includes the certificate of analysis (description, identification, assay, related substances), stability data for the marketed pack, and the site GMP certificate. Shelf life: 24 months. The full CTD dossier and the authority assessment file are supplied as part of a registration order; routine shipments carry the COA and stability data only.

Do you supply amoxicillin + clavulanic acid in paediatric ratios?

We supply both the 400/57 mg chewable tablet and the 200/28.5 mg per 5 mL oral suspension presentations used in paediatric formularies.

How do you handle stewardship restrictions?

Watch-group orders are supplied against documented purchase requirements. We can provide AWaRe classification reference material to support your tender or formulary documentation.

Companion Products — Antibacterials

Browse the full Antibacterials range; all Suspensions; the complete product catalogue.

Request a Quotation for Amoxicillin Clavulanate Suspension 200/28.5mg/5mL

Tell us the monograph, pack size and quantity required for Amoxicillin Clavulanate Suspension 200/28.5mg/5mL 200mg, together with the destination market, and the quotation will state lead time and the documents that ship with the batch. Samples for registration can be added to the same order.

Request a quotation

Sources & Regulatory Notes

Reference information only. The published guidance summarised on this page is quoted for professional and regulatory-context purposes and does not constitute medical advice, a prescribing recommendation or a promotion of any product for a particular indication. Prescribing decisions must follow the approved product information and national treatment guidelines in the market of use.

<< return to products